QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

Phase 1 Not yet recruiting 21 enrolled Wan-Guang Zhang Qilu Pharmaceutical Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase I trial to assess the safety and preliminary efficacy of QL1706 in Treating Advanced Hepatocellular Carcinoma Patients refractory to prior immunotherapy.

Timeline

Start: 2025-02-01
Primary completion: 2026-08-01
Completion: 2026-08-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QL1706	Monoclonal antibody	7.5 mg/kg	Intravenous

QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

Summary

Timeline

Drugs

Indications